A Long-Term Safety Extension Study of WA19926 in Participants With Rheumatoid Arthritis
Status:
Completed
Trial end date:
2014-12-01
Target enrollment:
Participant gender:
Summary
This extension study of WA19926 will assess the long-term safety and the efficacy of
RoActemra/Actemra (tocilizumab) treatment in participants with rheumatoid arthritis.
Participants who have completed the core study WA19926 are eligible to participate.
Participants will receive RoActemra/Actemra 8 mg/kg intravenously every 4 weeks. The
anticipated time on study drug is 104 weeks.